Macrocyclic lactones: distribution in plasma lipoproteins of several animal species including humans

https://doi.org/10.1016/j.cca.2004.07.011Get rights and content

Abstract

We studied the in vitro distribution of macrocyclic lactones (MLs), lipophilic anthelmintic drugs, in the plasma of several animal species including humans. First, in vitro spiking of goat plasma was performed with ivermectin, moxidectin, abamectin, doramectin, or eprinomectin. In parallel, goats were treated with subcutaneous injection of ivermectin. Then, cow, sheep, rabbit, pig, and human plasma were spiked with moxidectin. Four fractions were separated using KBr density gradient ultracentrifugation: very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and lipoprotein-deficient fraction. Cholesterol was analyzed by enzymatic assay and MLs by high-performance liquid chromatography. An average of 96% of MLs was associated with lipoproteins. The five MLs studied distributed similarly into goat plasma fractions with a preferential association with HDL (80–90%). Ivermectin partitioning in goat plasma was similar after in vitro spiking and in vivo treatment. In species displaying various lipoprotein profiles, moxidectin was also mainly associated with HDL. However, in human plasma, moxidectin was associated with a lesser extent to HDL (70%) and more to LDL (22%) when compared to other animal species. A relation between the plasma cholesterol content and pharmacokinetics of the drug is suggested. Our finding will allow further exploration of intestinal lymphatic absorption and milk elimination of these compounds—mechanisms in which lipoproteins are involved. In addition, possible improvements of new drug delivery systems are suggested.

Introduction

Macrocyclic lactones (MLs) are potent parasiticides widely used for control of internal and external parasites in domestic animals and livestock. Ivermectin, the semisynthetic derivative of avermectin B1, is also used in humans for the treatment of onchocerciasis, lymphatic filariasis, and scabies (Tagboto and Townson, 1996, Dourmishev et al., 1998). Commercially available ivermectin, eprinomectin, abamectin, and doramectin belong to the avermectin family, whereas moxidectin is a member of the milbemycin family (Fig. 1) currently under development in humans (Cotreau et al., 2003). These compounds are hydrophobic molecules characterized by a broad spectrum of activity with remarkable long-lasting efficacy. A large number of pharmacokinetic studies are available for these drugs, reporting a large volume of distribution, long residence time, extensive elimination in milk during lactation (Hennessy and Alvinerie, 2002), and an influence of adiposity on their pharmacokinetic behaviour (Craven et al., 2002). Thus, one of the major factors contributing to the disposition of these compounds is certainly the extent of release or exchange between the lipid reserve and bloodstream. Because the presence of MLs in the plasma and at the location of the parasite are closely correlated (Lifschitz et al., 2000), their partitioning into plasma components becomes a determinative factor for drug disposition and efficacy. Regarding their high affinity for fat tissues, we hypothesized that MLs may associate preferentially to lipoproteins in plasma. Lipoproteins are macromolecules of lipid and protein commonly involved in the transport of cholesterol, cholesteryl ester, triacylglycerol, and phospholipid, through vascular and extravascular body fluids. They also transport a wide number of hydrophobic xenobiotics within the bloodstream (Wasan and Cassidy, 1998). The interaction of drugs such as amphotericin B, cyclosporine, annamycin, and nystatin with lipoproteins has been reported to influence their pharmacokinetic behaviour, pharmacological activity, and toxicity (Wasan and Cassidy, 1998). As far as ivermectin is concerned, very few data mentioning that all the systemic drugs were associated with the plasma are available. The binding of ivermectin to serum albumin has been postulated in patients with onchocerciasis (Klotz et al., 1990). In dogs, serum albumin and lipoproteins have been shown to bind ivermectin to a similar extent (Rohrer and Evans, 1990).

The aim of this study was to examine the in vitro partitioning of commercialized MLs into plasma components. In a first step, we have studied the ability of five different MLs belonging to the structurally related avermectin and milbemycin families to associate with plasma components in the goat, representative of ruminants in terms of the plasma lipoprotein profile. In a second step, the ability of moxidectin to associate with plasma components was studied in five different animal species and humans.

Section snippets

Animal maintenance and treatment

Alpine goats (Capra hircus) weighing 25–30 kg (12–15 months, n=10) were housed in our animal facilities in concrete pens, fed barley hay, and commercial concentrates (Toulgrain, France) with free access to water. Three goats were treated with ivermectin (Ivomec; Merial, France) by subcutaneous administration (0.2 mg/kg), while seven goats did not receive any ML treatment. Male pigs (Sus domesticus, n=5) were housed in our animal facilities. Cows (Boss spp., n=5), male sheep (Ovies aries, n=5),

Distribution of different MLs in goat plasma components

Goat plasma samples spiked with different MLs were fractionated using KBr density gradient ultracentrifugation. This technique has been previously validated to separate plasma lipoproteins of different animal species (Terpstra et al., 1981). It allowed rapid and accurate separation of the three major plasma lipoprotein fractions [very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL)] and a lipoprotein-deficient fraction (LPDF), which contained

Discussion

Although the partitioning of hydrophobic drugs into plasma components represents a pivotal step for the drug distribution in the organism, this point has not been documented for MLs. The ability of five different MLs to associate in vitro with plasma components was studied in the goat, which is representative of ruminants as far as the lipoprotein profile is concerned. The three major lipoprotein fractions (VLDL, LDL, and HDL) and a lipoprotein-deficient fraction that contained mainly aqueous

Acknowledgements

We are grateful to Prof. Bertrand P. Perret for helpful discussions.

References (37)

Cited by (45)

  • Free drug percentage of moxidectin declines with increasing concentrations in the serum of marsupials

    2024, International Journal for Parasitology: Parasites and Wildlife
  • Extraction and analysis of moxidectin in wombat plasma and faeces

    2024, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
  • Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing

    2020, Journal of Pharmaceutical Sciences
    Citation Excerpt :

    Total ivermectin concentrations were simulated because protein binding in the lung has not been assessed, but it is likely the free drug concentration is significantly lower than the 772 ng/mL peak lung concentration simulated which reinforces the need for an inhalational dose. Ruminants such as cattle have similarly high plasma binding compared to humans (96–99%), and total ivermectin concentration was assessed by Lifschitz and colleagues.12,22 Also, because of the similarity in plasma binding of ivermectin between species, the Kp,lung/F was considered species-independent due to the assumed similar impact plasma binding would have on distribution which is an assumption commonly made in physiologically based pharmacokinetic modeling.23

  • Review of the Eprinomectin effective doses required for dairy goats: Where do we go from here?

    2020, Veterinary Parasitology
    Citation Excerpt :

    Regarding EPM according to the same way, twice the cattle dose in goats raises question. Indeed, the EPM body clearance in goats is 4.8 times greater than in cattle (J. Guyonnet and H. Karembe - CEVA, personal communication), a ratio similar to ivermectin (González Canga et al., 2009), with a quite similar Pour-On bioavailability and no significant difference in the unbound fraction between the two species (Bassissi et al., 2004). However, this approach does not take into account the pharmacokinetics aspects of persistence, whose influence on adult nematode mortality remains unclear, especially when the EPM sensitivity is reduced.

  • Development and validation of a method for simultaneous determination of trace levels of five macrocyclic lactones in cheese by HPLC-fluorescence after solid–liquid extraction with low temperature partitioning

    2019, Food Chemistry
    Citation Excerpt :

    Moreover, owing to their lipophilic proprieties, MLs have long-term persistence in the animal body. Several pharmacokinetic studies are available for these compounds, reporting a large volume of distribution, long residence time and elimination in milk during lactation (Cerkvenik et al., 2002, 2004; Bassissi, Alvinerie, & Lespine, 2004; Wen et al., 2010; Campbell, Pairis-Garcia, Campler, Moraes, & Mccutcheon, 2017). When present in milk, ML contamination may persist in dairy products.

  • On-line restricted access molecularly imprinted solid phase extraction of ivermectin in meat samples followed by HPLC-UV analysis

    2016, Food Chemistry
    Citation Excerpt :

    Ivermectin is a semi-synthetic antiparasitic drug from the macrolytic lactone family, extensively used in cattle raising due to its good performance against several parasites, as nematodes and arthropods (Giannetti et al., 2011). It is a lipophilic molecule, which is able to accumulate in adipose tissues and muscles, despite the low dosages often used in bovines (Bassissi, Alvinerie, & Lespine, 2004; Schenck & Lagman, 1999). If the withholding period, between the last application and the slaughter, is not respected, residues of ivermectin can be found in the meat, causing problems to the consumers, as embryotoxicity, for example (Wang, Wang, Liu, & Liu, 2009).

View all citing articles on Scopus
View full text